tiprankstipranks
Trending News
More News >
I-Tech AB (SE:ITECH)
:ITECH
Sweden Market

I-Tech AB (ITECH) AI Stock Analysis

Compare
3 Followers

Top Page

SE:ITECH

I-Tech AB

(ITECH)

Select Model
Select Model
Select Model
Outperform 75 (OpenAI - 5.2)
Rating:75Outperform
Price Target:
kr61.00
▲(13.38% Upside)
Strong financial performance (high profitability, strong cash conversion, and zero-debt balance sheet) is the primary driver of the score. This is tempered by weak technicals (price below key moving averages and negative MACD). Valuation is supportive with a moderate P/E and solid dividend yield.

I-Tech AB (ITECH) vs. iShares MSCI Sweden ETF (EWD)

I-Tech AB Business Overview & Revenue Model

Company DescriptionI-Tech AB, a bio-technology company, develops and commercializes fouling prevention products in Sweden. The company offers Selektope, a bio-repellent ingredient for marine coatings that provide hard fouling prevention for ships. Selektope prevent barnacles from settling on coated surfaces by temporarily activating the swimming behaviour of barnacle larvae. It serves marine coatings industry. The company was founded in 2000 and is based in Mölndal, Sweden.
How the Company Makes Money

I-Tech AB Financial Statement Overview

Summary
Strong fundamentals: profitable growth (TTM revenue 187.2m, +10.6%) with high margins (EBIT ~28.4%, net ~22.0%), strong free cash flow (FCF 58.0m; ~1.00x net income) and accelerating FCF growth (+27.7%). Balance sheet is very conservative with zero debt and strong ROE (~25.1%). Main risk is margin pressure versus 2023–2024 levels and historical cash flow volatility (negative in 2021).
Income Statement
TTM (Trailing-Twelve-Months) revenue is 187.2m with continued growth (+10.6%), following very strong expansion in 2022–2024. Profitability is a key strength: TTM gross margin is ~49.5% and operating profitability is high (EBIT margin ~28.4%), supporting a strong net margin (~22.0%). A notable positive is the clear turnaround from losses in 2020–2021 to consistently strong profits from 2022 onward. The main watch-out is that TTM gross margin is lower than 2023–2024 levels, suggesting some margin pressure even as earnings remain robust.
Balance Sheet
The balance sheet is very conservative, with zero total debt in TTM (Trailing-Twelve-Months) and a strong equity base (168.0m equity vs. 190.3m assets). Returns are also strong, with TTM return on equity around 25.1%, reflecting efficient profitability without reliance on leverage. Prior years show only minimal debt usage and low debt-to-equity when present, reinforcing financial flexibility. The primary limitation is that the dataset doesn’t provide liquidity details (e.g., cash/current assets), but leverage risk appears low.
Cash Flow
Cash generation is strong and high quality: TTM (Trailing-Twelve-Months) operating cash flow is 58.2m and free cash flow is 58.0m, with free cash flow closely matching net income (~1.00x), indicating solid earnings conversion. Free cash flow growth is very strong in TTM (+27.7%), accelerating from 2024. The main weakness is historical volatility—cash flow was negative in 2021—though results have been consistently positive and improving since 2022.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue187.24M179.45M120.86M83.63M52.90M52.82M
Gross Profit92.62M95.22M63.54M45.13M27.48M25.18M
EBITDA61.19M54.31M30.34M18.06M1.60M3.02M
Net Income41.11M39.01M20.20M10.62M-2.65M-4.81M
Balance Sheet
Total Assets190.29M173.11M152.44M125.41M115.12M120.18M
Cash, Cash Equivalents and Short-Term Investments135.73M100.16M83.26M52.75M35.01M40.98M
Total Debt0.007.79M0.002.25M4.29M8.62M
Total Liabilities22.29M15.73M16.20M9.37M10.19M13.58M
Stockholders Equity168.00M157.39M136.24M116.03M104.94M106.60M
Cash Flow
Free Cash Flow58.03M35.04M32.76M20.06M-2.43M4.88M
Operating Cash Flow58.16M35.17M35.14M20.13M-1.70M5.39M
Investing Cash Flow-497.00K-408.00K-2.38M-822.00K-928.00K-558.00K
Financing Cash Flow-16.20M-17.86M-2.25M-1.56M-3.35M-2.79M

I-Tech AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
kr623.88M15.443.31%
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
50
Neutral
kr1.06B-3.71131.20%32.28%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:ITECH
I-Tech AB
53.20
-1.81
-3.29%
SE:ONCO
Oncopeptides AB
4.28
3.02
239.56%
DE:8F8
SynAct Pharma AB
2.14
1.28
148.84%
DE:30S
Saniona AB
2.02
1.47
267.27%
DE:6XP
Xspray Pharma AB
2.75
0.04
1.48%
DE:7V3
Cantargia AB
0.50
0.37
296.83%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jan 04, 2026